Reading this on a mobile device? Try our optimized mobile version here:

March 28, 2013Faster News for FasterCures

  Top News 
  Science and Technology 
  • Gene discoveries open treatment targets for 2 blood disorders
    An international team of researchers says the discovery of two genetic mutations has yielded the possibility of new ways to treat beta-thalassemia and hemochromatosis. Blocking the macrophages that attach to erythroblasts could reduce red blood cell production, and changing the Tmprss6 gene could halt the body's use of iron. The findings were published in Nature Medicine and the Journal of Clinical Investigation. (3/26) LinkedInFacebookTwitterEmail this Story
  • "Small data" crucial for pharma in making business decisions
    The most important data challenge facing the pharmaceutical industry is the diversity of information necessary to make decisions at all points, writes Lee Feigenbaum of Cambridge Semantics, from discovery to development and commercialization. Relevant information can come from a wide range of sources and include both structured data, unstructured data and everything in between. While the necessary information may be "small data," its use is critical in making business decisions, Feigenbaum writes. FierceBiotechIT (3/27) LinkedInFacebookTwitterEmail this Story
  Finance and Economics 
  • Booz: Pharma should take individual approach to emerging markets
    A new analysis from consultant Booz & Co. notes that emerging markets may not be as lucrative for pharmaceutical companies as they hope. While pharma companies that enter these markets early can help shape them, the report noted that the size of countries classified as "emerging markets" varies, and the "ambitious targets" of some companies have not be met. "Companies should be aware that whilst there is huge potential here, variations within the emerging markets themselves require different and tailored approaches," the report cautions. PharmaTimes (U.K.) (3/28) LinkedInFacebookTwitterEmail this Story
  • Approval of Biogen's MS drug offers hope
    The FDA approved Biogen Idec's new oral drug for multiple sclerosis, Tecfidera (dimethyl fumarate), giving patients a welcome alternative to injected drugs. It was shown to lessen the number of flare-ups of the disease over a two-year period in two clinical trials involved 2,600 patients, and investors anticipate the new drug will become a top seller for treating MS. Xconomy/Boston (3/27) LinkedInFacebookTwitterEmail this Story
  • Biologics, SCOTUS' take on patent settlements boost Big Pharma
    Supreme Court justices expressed skepticism that patent settlements between brand-name and generic-drug makers should be unilaterally declared anti-competitive, writes Bruce Japsen. Generic drugs have cut into profits as Big Pharma has struggled to fill pipelines, and the news boosted stock values. Big Pharma is increasingly focused on developing complex biologic drugs to treat diseases such as cancer, multiple sclerosis and autoimmune disorders. Forbes (3/27) LinkedInFacebookTwitterEmail this Story
  Society and Ethics 
  • Scientists fret over patented genes
    Patents on short DNA sequences, aggregated together, cover the entire human genome, and patents on long sequences cover 41% of the human genome, researchers write in Genome Medicine. Enforcement of the patents could impede research and development of new drugs and diagnostics, the researchers said. Genetic Engineering & Biotechnology News (3/27) LinkedInFacebookTwitterEmail this Story

FasterCures / The Center for Accelerating Medical Solutions is a nonprofit think tank and catalyst for action that works across sectors and diseases to improve the effectiveness and efficiency of the medical research enterprise. FasterCures, a center of the Milken Institute, is nonpartisan and independent of interest groups.

Subscriber Tools
Print friendly format | Web version | Search past news | Briefs by date | Privacy policy

Contact Us
FasterCures / The Center for Accelerating Medical Solutions
1101 New York Avenue, NW
Suite 620
Washington, DC 20005
(202) 336-8900 |
Media Inquiries
Cecilia Arradaza
Director of Communications

 Recent FasterCures SmartBrief issues:   Lead Editor:  Lisa Gough
Distributed by:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information